Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD9496 in Women With Estrogen Receptor Positive HER-2 Negative Advanced Breast Cancer
Phase of Trial: Phase I
Latest Information Update: 26 Jun 2019
Price : $35 *
At a glance
- Drugs AZD 9496 (Primary)
- Indications Adenocarcinoma; Advanced breast cancer
- Focus Adverse reactions; First in man
- Sponsors AstraZeneca
- 21 Jun 2019 Status changed from active, no longer recruiting to completed.
- 23 Jan 2019 Planned End Date changed from 31 Dec 2018 to 31 Dec 2019.
- 31 Aug 2018 Biomarkers information updated